Al-Saffar A, Lennernäs H, Hellström PM. Gastroparesis, metoclopramide, and tardive dyskinesia: risk revisited. Neurogastroenterol Motil. 2019;31:e13617.
Austedo® (deutetrabenazine) [prescribing information]. Parsippany, NJ; Teva Pharmaceuticals USA, Inc: Approved 2017. Revised February 2020.
Bergman H, Walker DM, Nikolakopoulou A, et al. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess. 2017;21:1-218.
Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75.
Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264-e278.
Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785-794.
Citrome L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2017;383:199-204.
Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care. 2007;12(suppl):1-12.
Citrome L, Saklad SR. Revisiting tardive dyskinesia: focusing on the basics of identification and treatment. J Clin Psychiatry. 2020;81:TV18059AH3C.
Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003-2010.
Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476-484.
Ingrezza® (valbenazine) [prescribing information]. San Diego, CA; Neurocrine Biosciences, Inc: Approved 2017. Revised April 2020.
Kane JM, Correll CU, Nierenberg AA, et al; Tardive Dyskinesia Assessment Working Group. Revisiting the abnormal involuntary movement scale: proceedings from the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018;79:17cs11959.
Mehta SH, Morgan JC, Sethi KD. Drug-induced movement disorders. Neurol Clin. 2015;33:153-174.
Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76:779-787.
Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced Parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Neurol Ther. 2018;7:233-248.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Kapil Sethi, MD

Emeritus Professor
Neurology
Medical College of Georgia
Augusta, Georgia

Disclosures

Disclosure: Kapil Sethi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Neurocrine

Panelists

Karen Anderson, MD

Professor
Neurology and Psychiatry
Georgetown University School of Medicine
Washington, DC

Disclosures

Disclosure: Karen Anderson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Azevan; Lundbeck; Novartis; Teva

Cynthia Comella, MD

Professor
Neurosurgery and Neurological Sciences
Rush Medical College
Chicago, Illinois

Disclosures

Disclosure: Cynthia Comella, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Acadia; Acorda; Aeon Pharmaceutical; Ipsen Pharmaceutical; Jazz; Lundbeck; Merz; Neurocrine; Revance

Editors

Lisa Brauer, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisa Brauer, PhD, has disclosed no relevant financial relationships.

Heather Lewin, MAT

Associate Director, Medscape, LLC

Disclosures

Disclosure: Heather Lewin, MAT, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Expert Perspectives in the Treatment Success of Tardive Dyskinesia

Authors: Kapil Sethi, MD; Karen Anderson, MD; Cynthia Comella, MD
CME / ABIM MOC Released: 10/22/2020; Reviewed and Renewed: 10/22/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 10/22/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for psychiatrists, neurologists, and primary care physicians.

The goal of this activity is to inform clinicians regarding the assessment and treatment of patients with tardive dyskinesia, including the use of vesicular monoamine transporter-2 (VMAT2) inhibitors.

Upon completion of this activity, participants will:

Have greater competence related to
- The development of personalized treatment regimens for patients experiencing tardive dyskinesia
- The assessment of the effectiveness of therapeutic interventions to manage tardive dyskinesia

Disclosures

Moderator

Kapil Sethi, MD

Emeritus Professor
Neurology
Medical College of Georgia
Augusta, Georgia

Disclosures

Disclosure: Kapil Sethi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Neurocrine

Panelists

Karen Anderson, MD

Professor
Neurology and Psychiatry
Georgetown University School of Medicine
Washington, DC

Disclosures

Disclosure: Karen Anderson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Azevan; Lundbeck; Novartis; Teva

Cynthia Comella, MD

Professor
Neurosurgery and Neurological Sciences
Rush Medical College
Chicago, Illinois

Disclosures

Disclosure: Cynthia Comella, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Acadia; Acorda; Aeon Pharmaceutical; Ipsen Pharmaceutical; Jazz; Lundbeck; Merz; Neurocrine; Revance

Editors

Lisa Brauer, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisa Brauer, PhD, has disclosed no relevant financial relationships.

Heather Lewin, MAT

Associate Director, Medscape, LLC

Disclosures

Disclosure: Heather Lewin, MAT, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Psychiatry & Mental Health

CME / ABIM MOC

Expert Perspectives in the Treatment Success of Tardive Dyskinesia

Authors: Kapil Sethi, MD; Karen Anderson, MD; Cynthia Comella, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 10/22/2020; Reviewed and Renewed: 10/22/2021

Valid for credit through: 10/22/2022, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to inform clinicians regarding the assessment and treatment of patients with tardive dyskinesia, including the use of VMAT2 inhibitors.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Kapil Sethi, MD

Panelists

Karen Anderson, MD

Cynthia Comella, MD

Editors

Lisa Brauer, PhD

Heather Lewin, MAT

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CME / ABIM MOC

Expert Perspectives in the Treatment Success of Tardive Dyskinesia

Target Audience and Goal Statement

Disclosures

Moderator

Kapil Sethi, MD

Panelists

Karen Anderson, MD

Cynthia Comella, MD

Editors

Lisa Brauer, PhD

Heather Lewin, MAT

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Expert Perspectives in the Treatment Success of Tardive Dyskinesia

Educational Impact Challenge